Answers are grounded in this paper and cite their sources.
CD22, an inhibitory receptor canonically expressed in B cells, is also present in microglia of the murine central nervous system. In the human brain, CD22 was predominantly found in oligodendrocytes, but also in a subset of brain-resident myeloid cells from patients with Alzheimer’s disease, while it is also expressed in peripheral monocytes and differentiated THP-1 cells. CD22 has been implicated as a negative regulator of microglial phagocytosis. Here, we demonstrate that genetic ablation of CD22 in APPPS1 transgenic mice, a widely used murine model of Alzheimer’s disease-like pathology, attenuates amyloid-β pathology and protects parvalbumin-positive interneurons in an age-dependent manner. Mechanistically, microglia and differentiated THP-1 cells lacking CD22 exhibit enhanced activation and phagocytosis following stimulation of the pattern-recognition receptor CLEC7A, mediated by increased SYK signaling. Conversely, activation of CD22 with the agonistic antibody epratuzumab suppresses activation of differentiated THP-1 cells. Our findings identify a CLEC7A-CD22-SYK signaling axis in both human and murine myeloid cells, in which CD22 functions as an inhibitory regulator of CLEC7A-mediated cell activation.
No takes yet. Share an insight, caveat, or question.
Tschui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: